Abstract
Chronic exposure of many human hepatoma cell lines to a low dose (LD) of doxorubicin induced a senescence-like phenotype (SLP) accompanied by enlargement of cells and increased senescence-associated β-galactosidase activity. LD doxorubicin-induced SLP was preceded by multinucleation and downregulation of multiple proteins with mitotic checkpoint function, including CENP-A, Mad2, BubR1, and Chk1. LD doxorubicin-treated cells eventually underwent cell death through mitotic catastrophe. When we investigated whether LD doxorubicin-induced cell death shares biochemical characteristics with high dose (HD) doxorubicin-induced apoptosis in Huh-7 cells, we observed that externalization of phosphatidyl serine and release of mitochondrial cytochrome c into the cytosol was associated with both types of cell death. However, propidium iodide exclusion assays showed that membrane integrity was lost in the initial phase of LD doxorubicin-induced cell death through mitotic catastrophe, whereas it was lost during the late phase of HD doxorubicin-induced apoptosis. Furthermore, HD doxorubicin-induced apoptosis but not LD doxorubicin-induced mitotic catastrophe led to transient activation of NF-κB and strong, sustained activations of p38, c-Jun N-terminal kinase, and caspases. Collectively, these results indicate that different doses of doxorubicin activate different regulatory mechanisms to induce either apoptosis or cell death through mitotic catastrophe.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- PBS:
-
phosphate-buffered saline
- TUNEL:
-
terminal deoxynucelotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling
- SDS–PAGE:
-
sodium dodecyl sulfate/polyacrylamide gel electorphoresis
- MAP:
-
mitogen-activated protein
- JNK:
-
c-Jun N-terminal kinase
- calcein-AM:
-
calcein-acetoxymethyl ester
- Etd-1:
-
ethidium homodimer-1
References
Acunas B and Rozanes I . (1999). Eur. J. Radiol., 32, 86–89.
Aebi U, Cohn J, Buhle L and Gerace L . (1986). Nature, 323, 560–564.
Baichwal VR and Baeuerle PA . (1997). Curr. Biol., 7, R94–R96.
Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G . (2004). Oncogene, 23, 2825–2837.
Chan GK, Jablonski SA, Sudakin V, Hittle JC and Yen TJ . (1999). J. Cell. Biol., 146, 941–954.
Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K and Roninson IB . (1999a). Cancer Res., 59, 3761–3767.
Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC and Roninson IB . (2000). Oncogene, 19, 2165–2170.
Chang BD, Swift ME, Shen M, Fang J, Broude EV and Roninson IB . (2002). Proc. Natl. Acad. Sci. USA, 99, 389–394.
Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J and Roninson IB . (1999b). Oncogene, 18, 4808–4818.
Chu K, Teele N, Dewey MW, Albright N and Dewey WC . (2004). Radiat. Res., 162, 270–286.
Davis RJ . (2000). Cell, 103, 239–252.
Decaudin D, Marzo I, Brenner C and Kroemer G . (1998). Int. J. Oncol., 12, 141–152.
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M and Campisi J . (1995). Proc. Natl. Acad. Sci. USA, 92, 9363–9367.
Dumont P, Burton M, Chen QM, Gonos ES, Frippiat C, Mazarati JB, Eliaers F, Remacle J and Toussaint O . (2000). Free Radic. Biol. Med., 28, 361–373.
Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA and Holt SE . (2002). J. Biol. Chem., 277, 35509–35515.
Gamen S, Anel A, Perez-Galan P, Lasierra P, Johnson D, Pineiro A and Naval J . (2000). Exp. Cell Res., 258, 223–235.
Gewirtz DA . (1999). Biochem. Pharmacol., 57, 727–741.
Gupta S . (2001). Life Sci., 69, 2957–2964.
He QY, Liang YY, Wang DS and Li DD . (2002). Int. J. Oncol., 20, 261–266.
Hendry JH and West CM . (1997). Int. J. Radiat. Biol., 71, 709–719.
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW . (2000). Science, 287, 1824–1827.
Hortobagyi GN . (1997). Drugs, 54, 1–7.
Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T and Harris CC . (1993). Carcinogenesis, 14, 987–992.
Kalitsis P, MacDonald AC, Newson AJ, Hudson DF and Choo KH . (1998). Genomics, 47, 108–114.
Kang MS, Lee HJ, Lee JH, Ku JL, Lee KP, Kelley MJ, Won YJ, Kim ST and Park JG . (1996). Int. J. Cancer, 67, 898–902.
Lanni JS and Jacks T . (1998). Mol. Cell. Biol., 18, 1055–1064.
Li Y and Benezra R . (1996). Science, 274, 246–248.
Liu L, Kwak YT, Bex F, Garcia-Martinez LF, Li XH, Meek K, Lane WS and Gaynor RB . (1998). Mol. Cell. Biol., 18, 4221–4234.
Lock RB and Stribinskiene L . (1996). Cancer Res., 56, 4006–4012.
Lu W, Li YH, He XF, Chen Y, Zeng QL and Qiu YR . (2002). Di. Yi. Jun. Yi. Da. Xue. Xue. Bao., 22, 524–526.
Mantel C, Braun SE, Reid S, Henegariu O, Liu L, Hangoc G and Broxmeyer HE . (1999). Blood, 93, 1390–1398.
Miranda EI, Santana C, Rojas E, Hernandez S, Ostrosky-Wegman P and Garcia-Carranca A . (1996). Mutat. Res., 349, 173–182.
Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, Ushio Y and Saya H . (2004). Oncogene, 23, 6548–6558.
Ono K and Han J . (2000). Cell Signal., 12, 1–13.
Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU, Kim ST, Chung JK, Hwang YJ, Lee HS, Kim CY, Lee YI, Chen TR, Hay RJ, Song SS, Kim WH, Kim CW and Kim YI . (1995). Int. J. Cancer, 62, 276–282.
Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K and Mavligit GM . (1988). Cancer, 61, 1884–1888.
Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B and Davis RJ . (1996). Mol. Cell. Biol., 16, 1247–1255.
Roninson IB, Broude EV and Chang BD . (2001). Drug Resist. Updat., 4, 303–313.
Ruth AC and Roninson IB . (2000). Cancer Res., 60, 2576–2578.
Sciarrino E, Simonetti RG, Le Moli S and Pagliaro L . (1985). Cancer, 56, 2751–2755.
Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T and Lee KS . (2002). J. Biol. Chem., 277, 32282–32293.
Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW . (1997). Cell, 88, 593–602.
Speth PA, Linssen PC, Boezeman JB, Wessels HM and Haanen C . (1987). Cancer Chemother. Pharmacol., 20, 305–310.
te Poele RH, Okorokov AL, Jardine L, Cummings J and Joel SP . (2002). Cancer Res., 62, 1876–1883.
Wang Y, Blandino G and Givol D . (1999). Oncogene, 18, 2643–2649.
Wang Y, Zhu S, Cloughesy TF, Liau LM and Mischel PS . (2004). Oncogene, 23, 1283–1290.
Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR and Templeton DJ . (1994). Nature, 372, 798–800.
Acknowledgements
This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (HMP-02-PJ1-PG3-20708-0003) and a grant from the KOSEF (R05-2004-000-10740-0) (to KSC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eom, YW., Kim, M., Park, S. et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24, 4765–4777 (2005). https://doi.org/10.1038/sj.onc.1208627
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208627
Keywords
This article is cited by
-
2D MOF-enhanced SPR detector based on tunable supramolecular probes for direct and sensitive detection of DOX in serum
Microchimica Acta (2024)
-
Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis
Scientific Reports (2023)
-
Cellular senescence triggers intracellular acidification and lysosomal pH alkalinized via ATP6AP2 attenuation in breast cancer cells
Communications Biology (2023)
-
Intracellular FGF1 protects cells from apoptosis through direct interaction with p53
Cellular and Molecular Life Sciences (2023)
-
Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system—from molecular mechanisms to therapeutic applications
Heart Failure Reviews (2022)